Cost-effectiveness of carrier screening for cystic fibrosis in Australia

Richard Norman, Kees van Gool, Jane Hall, Martin Delatycki, John A Massie

Research output: Contribution to journalArticleResearchpeer-review

16 Citations (Scopus)

Abstract

Background: Carrier screening for cystic fibrosis is not widely available in Australia, partly due to concerns regarding its cost-effectiveness. The benefit of information from pregnancy to pregnancy has not been widely considered in existing cost-effectiveness analyses. Methods: A decision tree was constructed estimating costs and outcomes from screening, including both initial and subsequent pregnancies. Effectiveness was expressed in terms of CF births averted. Costs were collected using a health service perspective. All costs and outcomes were discounted at 5% per annum. Results: Screening reduced the annual incidence of CF births from 34 to 14/100,000 births (an aggregate number of CF births of 100.9 and 41.9 respectively). In initial pregnancies, costs in the screening arm (A$16.6. million/100,000 births) exceed those in the non-screening arm (A$13.4. million/100,000 births). The incremental cost per CF birth in initial pregnancies is therefore approximately A$150,000. However, this was reversed for subsequent pregnancies, in that the pre-collected information reduces the incidence of CF in subsequent pregnancies at low additional costs. When aggregated, the results suggest screening is likely to be cost-saving. Conclusions: The introduction of national carrier screening for cystic fibrosis should be considered, as it is likely to reduce CF incidence at an acceptable (potentially negative) cost.

Original languageEnglish
Pages (from-to)281-287
Number of pages7
JournalJournal of Cystic Fibrosis
Volume11
Issue number4
DOIs
Publication statusPublished - Jul 2012
Externally publishedYes

Keywords

  • Australia
  • Cost-effectiveness
  • Cystic fibrosis
  • Economic evaluation
  • Screening

Cite this